Congresos

← vista completa

Publicado el 1 de abril de 2002 | http://doi.org/10.5867/medwave.2002.03.1180

El rol de los agentes bioterapéuticos en el tratamiento de la diarrea

The role of biotherapeutic agents in the treatment of diarrhea

Yvan Vandenplas

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Yvan Vandenplas

Université Libre de Bruxelles, Bruselas, Bélgica

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Vandenplas Y. The role of biotherapeutic agents in the treatment of diarrhea. Medwave 2002;2(03):e1180 doi: 10.5867/medwave.2002.03.1180

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/04/2002

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. Swords WE. Postnatal changes in selected bacterial groups of the pig colonic microflora. Biol Neonate. 1993;63(3):191-200. | CrossRef | PubMed
  2. Zhang H. Diet influences development of the pig (Sus scrofa) intestine during the first 6 hours after birth. J Nutr. 1998 Aug;128(8):1302-10. | PubMed
  3. Simon GL, Gorbach SL. Intestinal flora in health and disease Gastroenterology. 1984 Jan;86(1):174-93. | PubMed
  4. Roffe C. Biotherapy for antibiotic-associated and other diarrhoeas. J Infect. 1996 Jan;32(1):1-10. | CrossRef | PubMed
  5. Marteau P. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev. 1993 Sep;12(1-3):207-20. | CrossRef | PubMed
  6. Langhendries JP. Effect of a fermented infant formula containing viable bifidobacteria on the fecal flora composition and pH of healthy full-term infants. J Pediatr Gastroenterol Nutr. 1995 Aug;21(2):177-81. | CrossRef | PubMed
  7. Hamilton-Miller JMT. Probiotic" remedies are not what they seem. BMJ. 1996 Jan 6;312(7022):55-6. | PubMed
  8. Canganella F. A microbiology investigation on probiotic pharmaceutical products used for human health. Microbiol Res. 1997 Jul;152(2):171-9. | PubMed
  9. Simakachorn N. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children J Pediatr Gastroenterol Nutr. 2000 Jan;30(1):68-72. | CrossRef | PubMed
  10. S. Guandalini, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial.J Pediatr Gastroenterol Nutr. 2000 Jan;30(1):54-60. | CrossRef | PubMed
  11. Bliss DZ, et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med. 1998 Dec 15;129(12):1012-9. | PubMed
  12. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998 Sep-Oct;16(5):292-307. | CrossRef | PubMed
  13. Pessey JJ, et al. Short course therapy with cefuroxime axetil for acute otitis media: results of a randomized multicenter comparison with amoxicillin/clavulanate. Pediatr Infect Dis J. 1999 Oct;18(10):854-9. | CrossRef | PubMed
  14. Arvola T, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999 Nov;104(5):e64. | CrossRef | PubMed
  15. Surawicz et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989 Apr;96(4):981-8. | PubMed
  16. McFarland, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol. 1995 Mar;90(3):439-48. | PubMed
  17. McFarland, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994 Jun 22-29;271(24):1913-8 | CrossRef | PubMed
  18. Mc Farland LV,et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999 Jan;20(1):43-50 | CrossRef | PubMed
  19. Elmer GW, et al Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther. 1999 Dec;13(12):1663-8. | CrossRef | PubMed
  20. Guslandi M. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000 Jul;45(7):1462-4. | CrossRef | PubMed
  21. Berg R, et al. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis. 1993 Nov;168(5):1314-8. | CrossRef | PubMed
  22. Majamaa, et al. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr. 1995 Apr;20(3):333-8. | CrossRef | PubMed
  23. Sussman JI, et al. Clinical manifestations and therapy of Lactobacillus endocarditis: report of a case and review of the literature. Rev Infect Dis. 1986 Sep-Oct;8(5):771-6. | CrossRef | PubMed
  24. Rahman M. Chest infection caused by Lactobacillus casei ss rhamnosus. Br Med J (Clin Res Ed). 1982 Feb 13;284(6314):471-2. | CrossRef | PubMed
  25. Mackay AD. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect. 1999 May;5(5):290-292 | CrossRef | PubMed
  26. Saxelin M, Chuang NH, Chassy B, Rautelin H, Mäkelä PH, Salminen S, et al. Lactobacilli and bacteremia in southern Finland, 1989-1992. Clin Infect Dis. 1996 Mar;22(3):564-6. | CrossRef | PubMed
  27. Schoon Y, Schuurman B, Buiting AG, Kranendonk SE, Graafsma SJ. Aortic graft infection by Lactobacillus casei: a case report. Neth J Med. 1998 Feb;52(2):71-4. | CrossRef | PubMed
  28. Rogasi PG, Viganò S, Pecile P, Leoncini F. Lactobacillus casei pneumonia and sepsis in a patient with AIDS. Case report and review of the literature. Ann Ital Med Int. 1998 Jul-Sep;13(3):180-2. | PubMed
  29. Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S,et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis. 1999 May;28(5):1159-60. | CrossRef | PubMed
  30. Dobson SR, Baker CJ. Enterococcal sepsis in neonates: features by age at onset and occurrence of focal infection. Pediatrics. 1990 Feb;85(2):165-71 | PubMed
  31. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, Romulo RL, Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol. 1994 May;32(5):1148-53. | PubMed
  32. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol. 1995 Mar;90(3):439-48 | PubMed
  33. Roffe C. Biotherapy for antibiotic-associated and other diarrhoeas J Infect. 1996 Jan;32(1):1-10. | CrossRef
  34. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res. 1993 Nov;10(11):1615-9. | CrossRef | PubMed
  35. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos. 1989 Jul-Aug;10(4):353-64. | CrossRef
  36. Boddy AV, Elmer GW, McFarland LV, Levy RH. Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharm Res. 1991 Jun;8(6):796-800 | CrossRef | PubMed
  37. Rodrigues AC, Nardi RM, Bambirra EA, Vieira EC, Nicoli JR. Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol. 1996 Sep;81(3):251-6 | PubMed
  38. Rigothier MC, Maccario J, Gayral P. Inhibitory activity of saccharomyces yeasts on the adhesion of Entamoeba histolytica trophozoites to human erythrocytes in vitro. Parasitol Res. 1994;80(1):10-5. | CrossRef | PubMed
  39. Zbinden R, Microbiol Ecology in Health and Disease 1999;11:158-62. | CrossRef
  40. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells Infect Immun. 2000 Oct;68(10):5998-6004. | CrossRef | PubMed
  41. Rigothier MC, Maccario J, Vuong PN, Gayral P. Effects of Saccharomyces boulardii yeast on trophozoites of Entamoeba histolytica in vitro and in cecal amebiasis in young rats. Ann Parasitol Hum Comp. 1990;65(2):51-60. | PubMed
  42. Ducluzeau R, Bensaada M. Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice. Ann Microbiol (Paris). 1982 Nov-Dec;133(3):491-501
  43. Massot J. Bulletin de la Sociètè de Mycologie Mèdicale 1978;7:73-76
  44. Rodrigues AC, Nardi RM, Bambirra EA, Vieira EC, Nicoli JR. Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol. 1996 Sep;81(3):251-6 | PubMed
  45. Massot J. Bulletin de la Société de Mycologie Médicale 1977;6:45-48
  46. Czerucka D, Roux I, Rampal P. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3',5'-cyclic monophosphate induction in intestinal cells Gastroenterology. 1994 Jan;106(1):65-72 | PubMed
  47. Dias RS, Bambirra EA, Silva ME, Nicoli JR. Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Braz J Med Biol Res. 1995 Mar;28(3):323-5 | PubMed
  48. Vidon N, Huchet B, Rambaud JC. Influence of Saccharomyces boulardii on jejunal secretion in rats induced by cholera toxin. Gastroenterol Clin Biol. 1986 Jan;10(1):13-6 | PubMed
  49. Massot J, Desconclois M, Astoin J. Protection by Saccharomyces boulardii against Escherichia coli diarrhea in newborn mice Ann Pharm Fr. 1983 Feb;40(5):445-9. | PubMed
  50. Czerucka D. Méd Chir Dig 1997;26:157-9
  51. Pothoulakis C, Kelly CP, Joshi MA, Gao N, O'Keane CJ, Castagliuolo I, Lamont JT. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993 Apr;104(4):1108-15 | PubMed
  52. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999 Jan;67(1):302-7. | PubMed
  53. Massot J, Sanchez O, Couchy R, Astoin J, Parodi AL. Bacterio-pharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamster Arzneimittelforschung. 1984;34(7):794-7. | PubMed
  54. Castex F, Corthier G, Jouvert S, Elmer GW, Lucas F, Bastide M. Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study J Gen Microbiol. 1990 Jun;136(6):1085-9. | PubMed
  55. Zaouche A, Loukil C, De Lagausie P, Peuchmaur M, Macry J, Fitoussi F, et al. Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation, and intestinal adaptation after small-bowel resection in rats. Scand J Gastroenterol. 2000 Feb;35(2):160-5. | CrossRef
  56. Tutton PJ, Barkla DH. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells (review). Anticancer Res. 1987 Jan-Feb;7(1):1-12. Anticancer Research 1987;7:1-12. | PubMed
  57. Buts JP, De Keyser N, Kolanowski J, Sokal E, Van Hoof F. Maturation of villus and crypt cell functions in rat small intestine. Role of dietary polyamines. Dig Dis Sci. 1993 Jun;38(6):1091-8. | CrossRef | PubMed
  58. Buts JP. Pediatr Res 1986;20:192-196 | CrossRef | PubMed
  59. Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res. 1986 Feb;20(2):192-6. | CrossRef | PubMed
  60. Buts JP, De Keyser N, De Raedemaeker L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res. 1994 Oct;36(4):522-7. | CrossRef | PubMed
  61. Jahn HU, Ullrich R, Schneider T, Liehr RM, Schieferdecker HL, Holst H, Zeitz M. Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion. 1996;57(2):95-104 | CrossRef | PubMed